Walter J, Eludin Z, Drabovich A
Clin Proteomics. 2023; 20(1):42.
PMID: 37821808
PMC: 10568870.
DOI: 10.1186/s12014-023-09431-y.
Sassu C, Palaia I, Boccia S, Caruso G, Perniola G, Tomao F
Int J Mol Sci. 2021; 22(24).
PMID: 34948446
PMC: 8707281.
DOI: 10.3390/ijms222413650.
Gohara S, Yoshida R, Kawahara K, Sakata J, Arita H, Nakashima H
Mol Clin Oncol. 2021; 15(4):209.
PMID: 34462664
PMC: 8375037.
DOI: 10.3892/mco.2021.2372.
Hartnett E, Knight J, Radolec M, Buckanovich R, Edwards R, Vlad A
Cancers (Basel). 2020; 12(12).
PMID: 33322601
PMC: 7764119.
DOI: 10.3390/cancers12123733.
Sobhani N, DAngelo A, Wang X, Young K, Generali D, Li Y
Int J Mol Sci. 2020; 21(11).
PMID: 32521648
PMC: 7312027.
DOI: 10.3390/ijms21114087.
A platform for interrogating cancer-associated p53 alleles.
DBrot A, Kurtz P, Regan E, Jakubowski B, Abrams J
Oncogene. 2016; 36(2):286-291.
PMID: 26996664
PMC: 5031501.
DOI: 10.1038/onc.2016.48.
Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?.
Osumi H, Shinozaki E, Suenaga M, Kumekawa Y, Ogura M, Ozaka M
BMC Cancer. 2015; 15:760.
PMID: 26490659
PMC: 4618932.
DOI: 10.1186/s12885-015-1751-6.
Prognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-Analysis.
Garziera M, Montico M, Bidoli E, Scalone S, Sorio R, Giorda G
PLoS One. 2015; 10(10):e0140351.
PMID: 26451959
PMC: 4599823.
DOI: 10.1371/journal.pone.0140351.
Diagnostic relevance of autoantibody detection against inhibitors of apoptosis proteins in colon cancer and colon adenoma.
Hosono Y, Goto M, Kobayashi D, Kuribayashi K, Tanaka M, Watanabe N
Mol Clin Oncol. 2015; 3(3):595-600.
PMID: 26137273
PMC: 4471536.
DOI: 10.3892/mco.2015.502.
Rapid and Sensitive Detection of p53 Based on DNA-Protein Binding Interactions Using Silver Nanoparticle Films and Microwave Heating.
Mohammed M, Aslan K
Nano Biomed Eng. 2015; 6(3):76-84.
PMID: 25568812
PMC: 4283572.
DOI: 10.5101/nbe.v6i3.p76-84.
p53 Expression in a Malignant Mesothelioma Patient during Seven-Year Follow-up.
Koo S, Uh S, Kim D, Kim K, Kim Y
Tuberc Respir Dis (Seoul). 2014; 76(6):284-8.
PMID: 25024722
PMC: 4092160.
DOI: 10.4046/trd.2014.76.6.284.
Serum p53 Antibody Is Not Associated with p53 Immunoreactivity in Patients with Pancreatobiliary Cancers.
Umeda J, Itoi T, Sofuni A, Itokawa F, Kurihara T, Tsuchiya T
J Oncol. 2014; 2013:170625.
PMID: 24454372
PMC: 3880693.
DOI: 10.1155/2013/170625.
Secreted recombinant P53 protein from Pichia pastoris is a useful antigen for detection of serum p53: autoantibody in patients with advanced colorectal adenocarcinoma.
Abdelmoula-Souissi S, Zouari N, Miladi-Abdenadher I, Yaich-Kolsi O, Ayadi-Masmoudi I, Khabir A
Mol Biol Rep. 2013; 40(5):3865-72.
PMID: 23526366
DOI: 10.1007/s11033-012-2467-1.
Serum APE1 autoantibodies: a novel potential tumor marker and predictor of chemotherapeutic efficacy in non-small cell lung cancer.
Dai N, Cao X, Li M, Qing Y, Liao L, Lu X
PLoS One. 2013; 8(3):e58001.
PMID: 23472128
PMC: 3589448.
DOI: 10.1371/journal.pone.0058001.
NY-ESO-1 antibody as a novel tumour marker of gastric cancer.
Fujiwara S, Wada H, Kawada J, Kawabata R, Takahashi T, Fujita J
Br J Cancer. 2013; 108(5):1119-25.
PMID: 23403818
PMC: 3619069.
DOI: 10.1038/bjc.2013.51.
Autoantibodies against insulin-like growth factor‑binding protein-2 as a serological biomarker in the diagnosis of lung cancer.
Zhang Y, Ying X, Han S, Wang J, Zhou X, Bai E
Int J Oncol. 2012; 42(1):93-100.
PMID: 23165420
PMC: 3583617.
DOI: 10.3892/ijo.2012.1699.
Osteopontin is a tumor autoantigen in prostate cancer patients.
Tilli T, Silva E, Matos L, Faget D, Dias B, Vasconcelos J
Oncol Lett. 2012; 2(1):109-114.
PMID: 22870138
PMC: 3412504.
DOI: 10.3892/ol.2010.211.
Prognostic significance of anti-p53 and anti-KRas circulating antibodies in esophageal cancer patients treated with chemoradiotherapy.
Blanchard P, Quero L, Pacault V, Schlageter M, Baruch-Hennequin V, Hennequin C
BMC Cancer. 2012; 12:119.
PMID: 22448886
PMC: 3338390.
DOI: 10.1186/1471-2407-12-119.
Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis.
Rivlin N, Brosh R, Oren M, Rotter V
Genes Cancer. 2011; 2(4):466-74.
PMID: 21779514
PMC: 3135636.
DOI: 10.1177/1947601911408889.
Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies.
Vermeij R, Leffers N, van der Burg S, Melief C, Daemen T, Nijman H
J Biomed Biotechnol. 2011; 2011:702146.
PMID: 21541192
PMC: 3085500.
DOI: 10.1155/2011/702146.